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Abstract
Background: While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma,
there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy.
To date, most biomarkers of response have been identified in the tumors themselves. Biomarkers that could
be assessed from peripheral blood would be even more desirable, because of ease of access and reproducibility
of sampling.
Methods: We used mass cytometry (CyTOF) to comprehensively profile peripheral blood of melanoma patients, in
order to find predictive biomarkers of response to anti-CTLA-4 or anti-PD-1 therapy. Using a panel of ~ 40 surface and
intracellular markers, we performed in-depth phenotypic and functional immune profiling to identify potential
predictive biomarker candidates.
Results: Immune profiling of baseline peripheral blood samples using CyTOF revealed that anti-CTLA-4 and
anti-PD-1 therapies have distinct sets of candidate biomarkers. The distribution of CD4+ and CD8+ memory/
non-memory cells and other memory subsets was different between responders and non-responders to anti-
CTLA-4 therapy. In anti-PD-1 (but not anti-CTLA-4) treated patients, we discovered differences in CD69 and
MIP-1β expressing NK cells between responders and non-responders. Finally, multivariate analysis was used to develop
a model for the prediction of response.
Conclusions: Our results indicate that anti-CTLA-4 and anti-PD-1 have distinct predictive biomarker candidates. CD4+
and CD8+ memory T cell subsets play an important role in response to anti-CTLA-4, and are potential biomarker candidates.
For anti-PD-1 therapy, NK cell subsets (but not memory T cell subsets) correlated with clinical response to therapy. These
functionally active NK cell subsets likely play a critical role in the anti-tumor response triggered by anti-PD-1.
Background
Immune checkpoint blockade with anti-CTLA-4 and
anti-PD-1/PD-L1 has improved clinical responses and
long term survival benefit for patients with advanced
melanoma and other cancers [1–4]. Nevertheless, there
persists a need for predictive biomarkers that facilitate
patient selection and treatment decisions, since not all
patients respond, and some patients respond better to
one therapy versus another [5, 6].
Immune monitoring of peripheral blood is attractive
for generating predictive biomarkers for cancer im-
munotherapy, due to the ease of accessing blood versus
tumor tissue. Blood is also more homogeneous com-
pared to tumors, making the sampling of blood easier
and more consistent. However, the number of potential
immune cell subsets and functions to monitor, are large.
Most studies to date have used conventional flow cytom-
etry, which limits the number of markers that can be
simultaneously detected. To overcome this limitation,
we used mass cytometry (CyTOF®) to extensively detect
different cell lineages, activation markers, cytokines and
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cytotoxicity markers (Table 3). Unlike conventional flow cy-
tometry which uses fluorophore-tagged antibodies, CyTOF
uses metal ion tagged antibodies, allowing the combination
of a larger number of antibodies for multiparametric ana-
lyses. Moreover, CyTOF is based on the principle of mass
spectrometry for the detection of metal tags, avoiding the
spectral overlap seen with flow cytometry [7].
In this study, we analyzed pre-treatment peripheral
blood mononuclear cell (PBMC) samples from melan-
oma patients receiving anti-CTLA-4 or anti-PD-1, to in-
vestigate potential correlations in baseline immune
features and clinical outcomes. Using a combination of
various analytic approches, we identified distinct poten-
tial predictive biomarkers in PBMC for anti-CTLA-4
and anti-PD-1 treated patients.
Methods
Sample selection
In this retrospective study, 67 pre-treatment PBMC sam-
ples from patients treated with either anti-CTLA-4 or
anti-PD-1 monotherapy were collected in accordance with
an Institutional Review Board (IRB)-approved protocol.
All patients provided consent prior to blood collection.
Patients were treated with dosages and schedules that are
FDA-approved for the treatment of metastatic melanoma.
Baseline blood was drawn before the first administraton of
anti-CTLA-4 or anti-PD-1. Patients treated with other
therapeutics prior to or after the checkpoint blockade
monotherapy were not excluded, provided baseline
PBMCs were available. Patients who were treated with
both anti-CTLA-4 and anti-PD-1 (at entirely different
periods of time) were grouped into either the anti-
CTLA-4 or anti-PD-1 cohort, based on the availability
of baseline blood. Kaplan-Meier analysis showed that
median overall survival was 46.7 months in the anti-
CTLA-4 cohort, and was not yet reached (at 42 months)
for the anti-PD-1 cohort (Additional file 1: Figure S1A
and B). Median progression-free survival was 5 months
in the anti-CTLA-4 group, and 7 months in the anti-
PD-1 group (Additional file 1: Figure S1C and D).
Clinical responses such as complete response (CR), par-
tial response (PR), stable disease (SD), and progressive dis-
ease (PD) (disease progression within 180 days) were
determined based on Response Evaluation Criteria In
Solid Tumors (RECIST) 1.1 [8]. Patients were further cat-
egorized as responders based on progression-free survival
for at least 180 days, while non-responders were patients
who had disease progression within 180 days (Table 1).
Baseline PBMC samples from 40 patients treated with
anti-PD-1 included 21 responders and 19 non-responders.
Among these 21 patients, there were 2 CR patients, 12 PR
patients, and 7 SD patients. Baseline PBMC samples from
27 patients treated with anti-CTLA-4 included 12 re-
sponders and 15 non-responders. Of these samples, 1
non-responder and 2 responder samples were excluded
due to poor cell recovery (< 20,000 live intact cells col-
lected). This resulted in 24 samples available for analysis
in the anti-CTLA-4 cohort. Among the 10 responders,
there were 2 PR patients, and 8 SD patients. No complete
response patients were available. Among the 8 female pa-
tients treated with anti-CTLA-4, 4 were responders.
Among the 16 male patients, 6 were responders. In the
anti-PD-1 cohort, 8 out of 15 female patients, and 13 out
of 25 male patients were responders. Initial assessment
showed that age and gender did not affect the clinical re-
sponse of patients from either therapy (Table 1). Among
the 24 anti-CTLA-4 patients, 18 were treatment naïve.
Among the remaining 6 treatment experienced patients,
who were all non-responders, 3 had experienced chemo-
therapy, 1 had been given IFNγ therapy, and 2 had previ-
ously been treated with radiation therapy. Among the 40
anti-PD-1 patients, 14 were treatment naïve, 1 patient had
experienced prior chemotherapy, 1 had been treated with
NeoVax, and 1 with high dose IL-2. 23 patients had expe-
rienced prior checkpoint blockade therapy: among them,
3 had previously been given anti-PD-1 (nivolumab), and
20 had been treated with anti-CTLA-4 in various combi-
nations (Table 2).
PBMC collection and storage
Baseline pre-treatment blood was drawn according to the
treatment protocol. The blood samples were subsequently
processed at the Center for Immune-Oncology (CIO) of
the Dana-Farber Cancer Institute. Peripheral blood mono-
nuclear cells (PBMCs) were isolated from sodium heparin
vacutainer blood samples by density gradient separation
with Ficoll-Paque PLUS (GE Healthcare Biosciences, Upp-
sala, Sweden) within 6 h of collection. Blood was diluted
1:1 with phosphate buffered saline (PBS) and slowly lay-
ered on 12 ml of Ficoll-Paque PLUS in a 50 ml conical
tube by pipetting carefully down the side of the tube with
a transfer pipette. Tubes were centrifuged at 436 RCF for
20 min. PBMCs were aspirated from the density gradient
using a transfer pipette. The collected cells were washed,
and a small volume (10 μl) from each sample was used for
cell counting on a Countess automated cell counter (Invi-
trogen, Carlsbad, CA). Live and dead cells were distin-
guished by trypan blue staining. Cells were then pelleted
at 272 RCF for 5 min, re-suspended in Fetal Bovine Serum
(FBS) (Life Technologies, Carlsbad, CA) + 15% dimethyl-
sulfoxide (DMSO), and 4–6 × 106 cell aliquots were pre-
pared. Cells were frozen overnight at -80 °C @ -1 °C/min
and transferred to liquid nitrogen for cryogenic storage
until assay.
Sample preparation and staining for CyTOF
Patient samples were processed for intracellular cytokine
staining by CyTOF as previously described [9, 10].
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Briefly, frozen PBMC were thawed and washed twice in
complete medium (RPMI supplemented with Pen-Strep
and L-glutamine). All samples from the anti-CTLA-4 as
well as the anti-PD-1 cohorts, upon thawing, had viability
in the range of 89–98%, and most yielded 3-6 × 106 viable
cells. A few samples were low at 1.5 × 106, and some sam-
ples gave more than 100% recovery, suggesting that there
was some variability in the number of cells that were fro-
zen. All cell counts were obtained using a Vi-Cell XR cell
viability analyzer (Beckman Coulter, Brea, California). After
thawing, samples were split into 2 experimental conditions:
unstimulated and PMA+ Ionomycin, with 2 × 106 cells (or
maximum available) per condition. They were rested in
96-well U-bottom plates overnight at 37 °C, 5% CO2. After
resting, secretion inhibitors brefeldin A (5 μg/ml) and
monensin (5 μg/ml) (Sigma-Aldrich, St. Louis, MO) were
added to both unstimulated and PMA+ Ionomycin condi-
tions. Anti-CD107a antibody conjugated to 151Eu (Flui-
digm, South San Francisco, CA) was also added to both
conditions, concentration as recommended by the supplier.
Additionally, for PMA+ Ionomycin stimulation, we added
10 ng/ml PMA and 1 μg/ml Ionomycin, while the un-
stimulated samples were treated with only secretion inhibi-
tors along with anti-CD107a-151Eu antibody. All samples
were incubated for 4 h at 37 °C. Thereafter, 2 mM EDTA
was added for 15 min at room temperature. Cells were
washed twice in CyFACS buffer (1X diluted from 10X PBS,
(Rockland Immunochemicals, Pottstown, PA) supple-
mented with 0.1% BSA and 0.05% sodium azide). A cell-
surface antibody cocktail consisting of pre-conjugated
antibodies (Fluidigm, South San Francisco, CA) as well as
in-house conjugated antibodies (Table 3) was prepared in
CyFACS and added to the cells for 45 min on ice. All anti-
body cocktails were filtered using 0.1 μm spin filters (Milli-
pore, Darmstadt, Germany) to remove possible antibody
aggregates before staining. Cells were washed twice in
CyFACS after surface staining, and 1:3000 115In -DOTA
Maleimide (5 mg/ml) live/dead stain was added for 30 min
on ice. The cells were then fixed in 2% paraformaldehyde
(PFA) in PBS at 4 °C overnight. These fixed cells were
washed twice in 1X permeabilization buffer (eBioscience,
San Diego, CA). Intracellular staining cocktail, also consist-
ing of Fluidigm pre-conjugated as well as in-house conju-
gated antibodies was prepared in 1X permeabilization
buffer and added to the cells for 45 min on ice (Table 3).
After washing three times in CyFACS, cells were stained
with Intercalator-Ir (Fluidigm) diluted as per the manufac-
turer’s recommendations in 2% PFA in PBS, and incubated
for 20 min at room temperature. Finally, cells were washed
twice in CyFACS and three times in MilliQ water. EQ Four
Element Calibration Beads from Fluidigm were added as
per the manufacturer’s directions prior to running. Data
were acquired on a Helios mass cytometer (Fluidigm) in
batches over two major time frames. Principal component
analysis showed no significant difference between them
(data not shown).
CyTOF data pre-processing and subsequent analysis
Data were obtained in the form of .fcs files from the Helios
instrument. The addition of EQ Four Element Beads
Table 1 Age and gender distribution of selected patients
anti-CTLA-4 anti-PD-1
responders non-responders responders non-responders
Age < 30 0 1 0 0
30–39 0 1 2 0
40–49 1 4 2 2
50–59 3 0 6 6
60–69 4 5 4 6
> 70 2 3 7 5
Ave. age (years) 62.3 56.4 61.3 61.4
STDEV (years) 10.9 17.7 15.3 11.6
p value (U test) 0.35 0.81
Gender Female 4 4 8 7
Male 6 10 13 12
Clinical response CR 0 2
PR 2 12 (3 borderline CR)
SD 8 7
PD 14 19
Age and gender distribution of patients in the anti-CTLA-4 and anti-PD-1 cohorts in relation to clinical response are shown. More details regarding patient sample
selection can be found in the Materials and Methods section. p values shown are from U test between responders and non-responders. p < 0.05 was considered
statistically significant
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allowed us to use the MATLAB-based normalization tech-
nique using bead intensities as described [11]. We used the
Nolan Lab MATLAB normalizer available freely on github.
com (https://github.com/nolanlab/bead-normalization/rele
ases). Following this pre-processing, .fcs files were further
analyzed in FlowJo version 10.1 for Mac (FlowJo LLC, Ash-
land, OR), or uploaded to Cytobank (www.cytobank.org)
for subsequent viSNE and Citrus analysis (details below).
Before viSNE and Citrus analysis, sequential gating was per-
formed on Cytobank. 191Ir and 193Ir DNA intercalator and
140Ce beads, as well as the event length parameter were
used to discern intact singlets from debris and cell aggre-
gates. 115In-DOTA Maleimide live/dead staining was then
used to identify live intact singlets (Fig. 1a). A similar ini-
tial gating strategy to detect live intact singlets was used
while analyzing CyTOF data by FlowJo (Additional file 1:
Figure S2A). All other cell populations were identified
as indicated in the respective figures (Additional file 1:
Figure S2B-I). Data shown in this study are in the form
of relative frequencies as derived from FlowJo gating.
All results presented in this study are from unstimulated
samples, except when PMA+ Ionomycin stimulation is
explicitly stated. GraphPad Prism 6.0d (GraphPad Soft-
ware, Inc., La Jolla, CA) was used for graphing and statis-
tics. The non-parametric Mann-Whitney U test was used,
and p values less than 0.05 were considered significant (*p
< 0.05, **p < 0.01). Frequencies of cell subsets/expression
markers from FlowJo gating were used for multivariate
analysis (described below).
viSNE and citrus analysis
viSNE is an automated dimensionality reduction algo-
rithm available in CytoBank [12]. The normalized
CyTOF .fcs files of all patient baseline PBMC, and one
healthy donor PBMC, including both the unstimulated
and PMA + Ionomycin stimulated samples were
uploaded to CytoBank. Sequential gating was performed
on each file to separate live intact single cells from
beads, aggregates, and debris as described above (Fig.
1a). Subsequent analyses were performed on live intact
Table 2 Patient treatment history for anti-CTLA-4 and anti-PD-1 treated patients
Anti-CTLA-4 patients treatment history
Total patients Treatment
naïve
Treatment
experienced
Checkpoint blockade
experienced
Responders 10 10 0 0
Non-responders 14 8 6 0
Total patients 24 18 6 0
Anti-CTLA-4 patients treatment experienced
Treatment experienced Ave. months between end
of prior treatment and
anti-CTLA-4 therapy
Range (months)
Responders 0 N/A N/A
Non-responders 6 2.5 < 1~ 11
Anti-PD-1 patients treatment history
Total patients Treatment naive Treatment experienced Checkpoint blockade
experienced
Nivolumab
experienced
Responders 21 8 13 12 1
Non-responders 19 6 13 11 2
Total patients 40 14 26 23 3
Anti-PD-1 patients treatment experienced
Treatment experienced Ave. months between
end of prior treatment
and anti-PD-1 therapy
STDEV (months) U test p value
between groups
Responders 13 6.3 7.1 0.59
Non-responders 13 4.5 6.6
The above tables list the number of patients who were treatment naïve and treatment experienced in either the anti-CTLA-4 or anti-PD-1 cohort. In the anti-CTLA-
4 cohort, 6 out of 24 patients were treatment experienced. None of them had experienced prior checkpoint blockade therapies. The average and range of time
window (months) from end of prior therapy of any kind and start of anti-CTLA-4 are shown. Among anti-PD-1 patients, the majority of treatment experienced
patients had prior checkpoint blockade therapies (23/26). Of these, 3 had prior nivolumab (in combination or sequential therapies with ipilimumab and other
modalities). The average time window (months) from end of prior therapy of any kind and start of anti-PD-1 in both responders and non-responders are shown.
Standard deviation of the time window in responders and non-responders are listed. Mann-Whitney U test was used to compare responders and non-responders
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singlets. For viSNE analysis, patient .fcs files were cate-
gorized into responders and non-responders for either
anti-CTLA-4 or anti-PD-1 groups. 29 markers: CD25,
CD3, CD4, CD8, CD19, CD20, CD56, CD14, TCRγδ,
CD16, CD33, CD45RA, HLA-DR, CD27, CD28, CD38,
CD57, CD69, CCR7, CD127, CD154, CTLA-4, PD-1,
PD-L1, PD-L2, GranzymeB, CD107a, GM-CSF, MIP-1β
were used to build the map. Cytokines with low expres-
sion were excluded because they would not contribute
to the structure of the map. A total of 99,904 events
were extracted by the algorithm using equal sampling of
892 events per .fcs file. Once the maps were made, the
expression level and distribution of each marker of inter-
est could be visualized by coloring based on each one.
Citrus (cluster identification, characterization, and re-
gression) is an automated algorithm designed to discover
statistically significant stratifying features across known
endpoints [13]. In the Citrus analysis, anti-CTLA-4 and
anti-PD-1 files were assessed separately. Files were
grouped into responders and non-responders. Seven sur-
face lineage markers, CD19, CD4, CD8, CD3, CD33,
CD14, and CD56 were used as clustering channels. Un-
like SPADE and some other clustering algorithms, Citrus
presents events redundantly in the tree, with each parent
cluster containing all the events in its children, and chil-
dren of children. This starts with the center cluster,
which contains all events in the analysis. Each parent
cluster has no more than two direct children. This clus-
tering process continues until it reaches the user-defined
cluster size limit (set as a percentage of all events ana-
lyzed; we used 5%). A parent cluster may have only one
direct child cluster if the second cluster is below the size
limit. Each cluster has an identifying number associated
with it. Median signal intensity and cluster abundance
are two modes in Citrus, which are mutually exclusive.
In our analysis, we focused on the signal intensity mode,
but also ran in cluster abundance mode. The median
signal intensities of 29 out of 46 CyTOF channels were
analyzed, with all seven lineage markers used for cluster-
ing excluded by default in the algorithm, and all non-
protein channels: Time, event_length, 115In_Dead,
140Ce_Beads, 191IrDNA1, 193IrDNA2, center, offset,
width, residual excluded by the investigator. Nearest
Shrunken Centroid (PAMR) model was selected as the
predictive algorithm.
Multivariate analysis
The 210 cell population fractions generated in FlowJo
were ranked using a Wilcoxon Ranksum test according
to response. Specifically, we used the wilcox.test function
of the stats package in R to generate raw p-values, which
were corrected for the false discovery rate using the
Benjamini-Hochberg procedure [14]. In addition, the
fractions generated by FlowJo were used as independent
Table 3 CyTOF panel for the phenotypic and functional analysis
of immune cell subsets
Metal label Specificity Antibody clone
1 115In Dead cells n/a
2 140Ce Beads n/a
3 141Pr CD25 M-A251
4 142Nd CD19 HIB19
5 143Nd IL-10 JES3-9D7
6 144Nd IL-4 MP4-25D2
7 145Nd CD4 RPA-T4
8 146Nd CD8 RPA-T8
9 147Sm CD20 2H7
10 148Nd CD57 HCD57
11 149Sm CTLA-4 14D3
12 150Nd MIP-1β D21–1351
13 151Eu CD107a H4A3
14 152Sm TNFa Mab11
15 153Eu CD45RA HI100
16 154Sm CD3 UCHT1
17 155Gd CD28 L293
18 156Gd CD38 HB-7
19 157Gd HLA-DR G46–6
20 158Gd CD33 WM53
21 159 Tb GMCSF BVD2-21C11
22 160Gd CD14 M5E2
23 161Dy IFNγ 4S.B3
24 162Dy CD69 FN50
25 163Dy TCRγδ B1
26 164Dy IL-17 N49–853
27 165Ho CD127 A019D5
28 166Er IL-2 MQ1-17 h12
29 167Er CD27 L128
30 168Er CD154 (CD40L) 24–31
31 169Tm CCR7 150503
32 170Er PD1 EH12.1
33 171Yb Granzyme B GB11
34 172Yb PD-L2 24F.10C12
35 173Yb Perforin B-D48
36 174Yb CD16 3G8
37 175Lu PD-L1 29E.2A3
38 176Yb CD56 NCAM16.2
39 191Ir DNA1 n/a
40 193Ir DNA2 n/a
A 40-marker CyTOF panel for the phenotypic and functional analysis of immune
cell subsets in melanoma patients treated with anti-CTLA-4 or anti-PD-1
therapy is shown. The element and isotope of the metal tag conjugated
to each antibody and non-protein subject (italic) is indicated under the
‘Metal Label’ column. ‘Specificity’ indicates the target recognized by the
metal-conjugated antibody or non-protein subject. 193Ir/195Ir DNA Intercalator
and 115In Maleimide DOTA live/dead stain facilitate the identification of live
intact singlets while calibration beads (140Ce) are important for data pre-
processing. Antibody clones are listed when applicable
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features to generate a biomarker based on an elastic net
classifier [15]. Since no independent dataset was avail-
able, a leave-one-out cross-validation (LOOCV) strategy
was used to ensure an unbiased estimation of classification
performance. Within each partition of the LOOCV one
sample was left out for testing, feature selection based on
a Wilcoxon test was performed to get a ranking of feature
importance and the top features were used to build an
elastic net prediction model, which was used to predict
the left out sample. This strategy is repeated until each
sample has been left out once. LOOCV allows for the de-
termination of the optimal number of features, and an es-
timation for the alpha and lambda parameters of the
elastic net model. For each model, both the area under the
receiver operating characteristic curve (AUC) and accur-
acy for the model that has a cutpoint equally weighing
false positive and false negative predictions are reported.
The optimal models were selected by maximizing AUC.
For the anti-CTLA-4-treated group, the optimal pa-
rameters were 4 features (Fig. 2), alpha: 0.0 and lambda:
0.001. For the models build on the anti-PD-1 treated
samples the optimal parameters were 25 features (data
not shown), alpha: 0.9 and lambda 0.002. Both random
forest [16] and shrunken centroid [17] classifiers were
compared to the elastic net with inferior classification
performance in both datasets. All analyses were per-
formed using the R and the glmnet, pamr, randomforest
and pROC packages.
Results
viSNE analysis of CyTOF data produces well-defined
immune subset maps in PBMCs
The dimentionality reduction tool viSNE [12] was
employed to turn high-dimensional CyTOF data from each
PBMC sample into a two-dimensional map of immune cell
subsets, with each dot in the map representing one event
(cell). Live intact single cells gated from the unstimulated
PBMC of a healthy donor (Fig. 1a) could be clearly grouped
into distinct subsets (Fig. 1b), including B cells (CD19
+CD20+), CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3
+CD8+), Natural Killer (NK) cells (CD3−CD56+CD16+/lo),
and monocytes (CD33+CD14+). Natural Killer T (NKT)
cells, (CD3+CD56+) as well as γδ T cells (CD3+TCRγδ+)
also form distinct T cell populations on the viSNE map.
(Fig. 1b). After PMA+ Ionomycin stimulation, there was a
clear shift in the location of various populations on the
viSNE map (Fig. 1c). These differences in viSNE patterns of
major immune cell clusters indicates that, in spite of being
the same cell type, viSNE can detect differences in their ex-
pression patterns, and assigns them somewhat altered
b
a c
Fig. 1 viSNE analysis of CyTOF data results in well-defined immune subset maps in PBMC. Preliminary gating of CyTOF data to define live intact
single cells, was performed in CytoBank. Then viSNE mapping of the healthy donor PBMC and patient baseline PBMC are shown. a All ungated
events were sequentially gated in Cytobank to identify live intact single cell events as described in Methods. a) 191Ir DNA1 and 140Ce beads
were used to identify cells. b) Singlets were identified by gating on cells positive for the DNA markers 191Ir DNA1 and 193Ir DNA2. c) Event
Length of singlets from b) was used to obtain intact singlets. d) Live intact singlets were obtained by gating for intact singlets from c) which were
negative for dead cell marker 115In maleimide DOTA. Subsequent viSNE analysis was performed using live intact single cell events obtained from d). b
viSNE map of healthy donor PBMC showing distinct immune subsets. The heat spectrum associated with each graph indicates the relative expression
level of each marker. c Various immune subsets were grouped into distinct islands on the viSNE map
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locations in 2-dimensional space. After stimulation, acti-
vated T cells are clustered together, but appear outside of
the original CD4+ or CD8+ bubbles as seen in the unstimu-
lated viSNE map (Fig. 1c, top and bottom panels).
viSNE maps were used to compare responders and
non-responders to anti-CTLA-4 and anti-PD-1 therap-
ies. The viSNE maps of patient baseline PBMCs shared
the same basic structure as the healthy donor (data not
shown). Closer examination revealed that the viSNE
maps of some patients were not well-structured, with
missing or significantly shrunken clusters in various sub-
sets. Stronger CD45RA intensity was observed in the
CD4+ and CD8+ compartments of non-responders to
anti-CTLA-4 therapy (Additional file 1: Figure S3). No
difference in CD45RA intensity was found in patients
treated by anti-PD-1 (data not shown). viSNE served to
visualize such differences well. However, it has limited
ability to provide quantifiable results, and we therefore
used manual analysis to further investigate the differ-
ences between responders and non-responders.
Differential distribution of CD4+ and CD8+ T cell memory
subsets in anti-CTLA-4 responders versus non-responders
The frequency of all major immune subsets was assessed
using conventional supervised gating on FlowJo (Fig. 1a
and Additional file 1: Figure S2B-I). In contrast to previ-
ous reports [18, 19], this analysis did not reveal obvious
differences in lymphocyte and monocyte frequencies be-
tween responders and non-responders to anti-CTLA-4 or
anti-PD-1 therapy (Additional file 1: Figure S2B and C).
The frequencies of the other immune subsets, including B
cells, T cells, NK cells, and NKT cells, as well as the CD8+
to CD4+ ratio, did not show significant differences be-
tween responders and non-responders to either therapy
(Additional file 1: Figure S2 D-I). There was also no differ-
ence in γδ T cell frequencies between responders and
non-responders. However, clone B1 was used for TCRγδ
staining, which could potentially have been affected by
simultaneous CD3 staining. Further investigation will be
needed to evaluate the potential of the γδ T cell popula-
tion as a biomarker.
Since anti-CTLA-4 [20, 21] and anti-PD-1 [22, 23] tar-
get T cell checkpoint signaling pathways, we focused our
attention on CD4+ and CD8+ T cells. We found that in
anti-CTLA-4 treated patients, responders had significantly
lower frequencies of CD45RA+ cells in both the CD4+ (p
= 0.038) and CD8+ (p = 0.019) T cell compartments
(Fig. 3a). The converse was also true for CD45RA− cells
(Fig. 3b). In anti-PD-1 treated patients, there were no ap-
parent differencs in CD45RA expression between re-
sponders and non-responders (Additional file 1: Figure
S4A and B). All samples were obtained prior to the initi-
ation of immunotherapy, indicating that baseline CD45RA
expression level in T cells correlates with clinical response
to anti-CTLA-4 but not anti-PD-1 treatment.
CD45RA expression, in conjunction with CCR7, can be
used to identify naïve (CD45RA+CCR7+), central memory
(Tcm, CD45RA−CCR7+), effector memory (Tem, CD45RA
−CCR7−) and terminal effector (Teff, CD45RA+CCR7−)
cells [24]. In the anti-CTLA-4 treated patients, we found
no significant differences in CD4+ T cell memory subsets
between responders and non-responders (Fig. 3c and d).
However, naïve T cells and Teff appeared lower in re-
sponders while Tcm and Tem tended to be lower in non-
responders, although these trends did not reach statistical
significance (Fig. 3c and d). Similar results were obtained
using CD27 in place of CCR7 to define [25, 26] these
memory T cell subsets (data not shown).
For CD8+ T cells, naïve and Teff tended to be lower in re-
sponders, although not statistically significant (Fig. 3e and f).
Conversely, the frequencies of Tcm and Tem cells were
higher in responders compared to non-responders to
anti-CTLA-4 therapy (Fig. 3e and f). Among these im-
mune subsets the CD8+ Tem frequency was significantly
higher in responders to anti-CTLA-4 (p = 0.008) (Fig. 3f).
In anti-PD-1 treated patients, there were no differences in
CD4+ or CD8+ memory T cell subsets (Additional file 1:
Figure S4 C-F). Since CD45RA− T cells include central
and effector memory T cells, our results show that base-
line memory CD4+ and CD8+ T cells, and CD8+ effector
memory T cells may be predictive biomarkers of response
to anti-CTLA-4 treatment.
cba
Fig. 2 Non-responders to anti-PD-1 had lower CD69 and MIP-1β expressing NK cells following PMA + Ionomycin stimulation. Pre-treatment PBMC
from melanoma patients who were responders or non-responders to anti-PD-1 therapy were stimulated with PMA + Ionomycin ex vivo, and analyzed
by CyTOF. Frequencies of (a) CD69+, (b) MIP-1β+ and (c) CD69+MIP-1β+ NK cells are shown. *p < 0.05
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MIP-1β and CD69 expressing NK cells are higher in
patients who respond to anti-PD-1 therapy
We further investigated the potential role of NK cell
populations in predicting outcome to anti-CTLA-4 and
anti-PD-1 therapy. In general, we gated NK cells as
CD56+CD16+ from CD3− lymphocytes. However, follow-
ing PMA + Ionomycin stimulation, CD16 is downregu-
lated, and so we modified this gate to detect CD56
+CD16lo NK cells, whose frequency was within 10% of
the CD56+CD16+ NK cell population in the correspond-
ing unstimulated sample. After analyzing the expression
of functional markers on NK cells, we found that re-
sponders to anti-PD-1 therapy had significantly higher
CD69+ NK cells (Fig. 4a) than non-responders, in PMA
+ Ionomycin stimulated PBMC. Also, the expression of
MIP-1β in NK cells after stimulation was higher in re-
sponders compared to non-responders (Fig. 4b). There
was no correlation between the expression of MIP-1β
and CD69, indicating that these are independent predic-
tors (data not shown). In order to investigate if combin-
ing MIP-1β and CD69 could provide greater predictive
value, we gated CD69 and MIP-1β double positive NK
cells, which formed a distinct CD69+MIP-1β+ population
(Additional file 1: Figure S5). This CD69+MIP-1β+ NK
cell population in stimulated samples seemed higher in
anti-PD-1 responders as compared to non-responders,
but did not reach statistical significance (p = 0.0538)
(Fig. 4c). In unstimulated samples, we did not observe
statistically significant differences between CD69+, MIP-
1β+, or CD69+MIP-1β+ NK cells between responders and
non-responders (data not shown). Interestingly, PMA+
Ionomycin stimulated samples from the anti-CTLA-4 co-
hort did not show any differences in CD69+, MIP-1β+ or
CD69+MIP-1β+ NK cells between responders and non-
responders (Additional file 1: Figure S6). This suggests
that CD69+ and MIP-1β+ NK cells are potential biomarker
candidates specific to anti-PD-1 (but not anti-CTLA-4)
immunotherapy.
In this study, our examination of Tregs (defined as
CD4+CD25+CD127lo) did not show any significant cor-
relation with response to anti-CTLA-4 or anti-PD-1
therapy (Additional file 1: Figure S7). We also did not
find any association between CTLA-4 and PD-1 expres-
sion on either CD4+ or CD8+ T cells with clinical benefit
(Additional file 1: Figure S8). The expression of PD-L1
and PD-L2 on all major immune subsets, including
monocytes and NK cells, also did not correlate with clin-
ical response (Additional file 1: Figure S9). We observed
a
c
e
b
d
f
Fig. 3 Melanoma patients who responded to anti-CTLA-4 therapy had higher frequencies of memory T cells in baseline PBMC. CyTOF data from
baseline PBMC of melanoma patients treated with anti-CTLA-4. Frequencies of (a) CD45RA+ cells in CD4+ and CD8+ T cell compartments; (b) CD45RA−
cells in CD4+ and CD8+ T cell compartments. c-f Memory subsets of CD4+ and CD8+ T cells in responders versus non-responders. c Frequencies of
naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RA−CCR7+) CD4+ T cells. d Frequencies of Effector Memory (Tem, CD45RA−CCR7−)
and Terminal Effector (Teff, CD45RA+CCR7−) CD4+ T cells. c Frequencies of naïve (CD45RA+CCR7+) and Central Memory (Tcm, CD45RA−CCR7+) CD8+ T
cells. d Frequencies of Effector Memory (Tem, CD45RA−CCR7−) and Terminal Effector (Teff, CD45RA+CCR7−) CD8+ T cells. *p < 0.05; **p < 0.01
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some variation in PD-L1 on monocytes (Additional file 1:
Figure S9A) and PD-L2 on NK cells, perhaps due to vari-
ability in antibody lots (Additional file 1: Figure S9D).
Both PD-L1 and PD-L2 were pre-conjugated antibodies
purchased from Fluidigm (South San Francisco, CA). Im-
portantly, within each cohort, the expression levels were
comparable, and we did not observe any differences be-
tween responders and non-responders. The expression of
intracellular cytokines such as IL-2, IL-4, Il-10, IFNγ,
GM-CSF, etc. was assessed, and not found to be pre-
dictive of response to anti-CTLA-4 or anti-PD-1 ther-
apy (data not shown). The only feature that was
associated with clinical outcome was Granzyme B in
NK cells, which was significantly higher in non-
responders to anti-PD-1 (p = 0.0054) (Additional file
1: Figure S10A). In spite of the statistical significance,
we observed that the expression levels were very high,
and the actual percentages in responders and non-
responders were close. We believe that further valid-
ation is needed to be able to accurately and conclu-
sively interpret these data. Granzyme B expression in
CD8+ T cells did not differ between responders and
non-responders (Additional file 1: Figure S10B).
Multivariate analysis helped to identify the optimal
combination of multiple features that best correlate
clinical response to either anti-CTLA-4 or anti-PD-1
therapy
Some strong correlations between clinical response and
baseline PBMC markers were identified through immune
phenotyping with our CyTOF panel (Table 3). However,
none of the parameters measured could distinctly separate
responders from non-responders, due to significant
overlap of the parameter values in both groups. In further
attempts to resolve this, a multivariate approach was
adopted to investigate if a combination of parameters
could distinguish responders and non-responders to anti-
CTLA-4/anti-PD-1 treatment with greater sensitivity and
specificity.
The multivariate analysis included all parameters gen-
erated by manual analysis. The frequency of each pheno-
typic and functional immune cell subset, including the
expression level of every surface and intracellular pro-
tein, were assessed as independent features in a multi-
variate test. In order to reduce redundant information
such as the reciprocity between CD45RA+ and CD45RA
−, only one feature instead of both were used in the ana-
lysis. Using the Wilcoxon Ranksum Test, all cell subsets
were ranked based on their feature importance with ad-
justed p values. Next, a leave-one-out cross-validation
(LOOCV) strategy was adopted to ensure unbiased clas-
sification with an elastic net classifier (as described in
Materials and Methods). As shown in Fig. 4, LOOCV
allowed the determination of an optimal number of fea-
tures for an elastic net model of prediction.
In the anti-CTLA-4 treated group, a combination of
four features were determined as optimal to predict clin-
ical response, with an AUC value of 0.729 (Fig. 5). The
features highlighted by the model include the frequen-
cies of Granzyme B+ NK cells, CD4+ Teff cells (CD4
+CD45RA+CD27−), CD45RA+CCR7+ TNFα+ CD4+ T
cells and HLADR−CD38− CD4+ T cells. These results
were somewhat in agreement with the univariate analysis
which highlighted memory subsets: CD45RA+ and
CD45RA− CD4+ and CD8+ T cells, as well as CD8+ Tem
cells as potential predictive markers. As per the
Fig. 4 Multivariate predictive models for response to anti-CTLA-4 treatment. Multivariate analysis based on the FlowJo gating of CyTOF data was
performed to generate a model that predicts clinical response to anti-CTLA-4 monotherapy. The heatmap is row-normalized and shows the four
features used by the model with the highest area under the curve (AUC). Each value in the heatmap corresponds to a cell population as determined by
manual gating, where red indicates a larger population and blue a smaller one. The signature coefficients (grey bars) on the left side indicate the elastic
net weights, which corresponds to the importance in the prediction model. The clinical response of each patient is indicated in green (responder) and
red (non-responder) as a horizontal bar above the heat map. The predictions of clinical response for each patient are indicated in grey (responders) and
black (non-responders), where the height of the vertical bar represents the probability output of the predictor. The receiver operating characteristic (ROC)
curve for the model is shown on the right
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univariate analysis, the Granzyme B expression in NK
cells tended to be higher in non-responders (p = 0.0054)
but was not significant after correction for multiple test-
ing (FDR = 0) (Additional file 1: Figure S10A).
A similar model was derived in the anti-PD-1 treated
group, however the optimal model based on twenty-five
features only achieves an AUC of 0.569 (data not
shown), indicating little prediction value.
Correlative features identified in FlowJo and multivariate
analysis can be further validated by the citrus algorithm
The unsupervised algorithm Citrus was used to further
validate the findings of the individual statistical tests and
the multivariate modeling [13]. In the ani-CTLA-4 study,
a predictive model was produced (Fig. 5a-c) that included
the signal intensities of CD45RA in multiple clusters in
CD4+ and CD8+ T cell branches, as well as CD38 expres-
sion in one of the CD4+ clusters and the base cluster,
which included all PBMC events (Fig. 5a and b). The
model also highlighted HLA-DR and PD-L1 expression
on an uncharacterized cluster (Fig. 5b), but this cluster ap-
pears very heterogeneous when we analyzed the exported
events by manual gating. PD-L2 expressing CD14+ mono-
cytes were selected by the automated model too, although
univariate analysis revealed that the difference between re-
sponders and non-responders were not significant. The
identification of CD45RA expression as the major feature
correlating with clinical response was consistent with the
observations from univariate and multivariate analyses.
However, Citrus was unable to precisely assess functional
subsets that are defined by the expression of a combin-
ation of parameters, such as memory T-cell subsets or
regulatory T cells (Tregs). There was no difference in the
frequencies of major immune subsets between responders
and non-responders, as analysed by the cluster abundance
test in Citrus, with no specific model generated.
In the anti-PD-1 treated cohort, no specific predictive
model was produced. This result is in accordance with
a
c
b
Fig. 5 Parameters that correlate with anti-CTLA-4 and anti-PD-1 clinical response were verified by the automated Citrus algorithm. CyTOF .fcs files
were analyzed using the Citrus algorithm to establish a predictive model for anti-CTLA-4 treatment. (a) Citrus clustering of immune subsets (represented
by metal_marker channels) based on CyTOF data from baseline PBMCs of anti-CTLA-4 treated patients are shown as graphs. The distribution of each
immune subset is presented as an individual graph. The heat spectrum associated with each graph indicates the expression level of each channel in a
cluster. (b) A Nearest Shrunken Centroid (PAMR) model described the minimum number of channels and clusters needed to distinguish responders from
non-responders to anti-CTLA-4 with the lowest error rate. (c) Comparisons of metal signal intensities (mean) of indicated channels are shown from left to
right: CD45RA (153Eu) in base CD4+ and CD8+ clusters, and PD-L2 (172Yb) intensity in the base monocyte cluster in responders vs. non-responders to
anti-CTLA-4 therapy. Two clusters from the Citrus predictive model in (b) are not demonstrated in (c) The cluster highlighted for the signal of HLA-DR
(157Gd) is not associated with any major immune subsets in this analysis. The cluster highlighted for the signal of CD38 (156Gd) is the base cluster of
total PBMC§. §CD38 expression on total PBMC was also assessed, and no significant difference between responders and non-responders was found in the
univariate analysis.
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the multivariate analysis that also did not yield any
strong correlatives. In spite of its limitations, Citrus
served as an unsupervised validation of the results ob-
tained from manual gating of the CyTOF data.
Effect of prior anti-CTLA-4 therapy on response to
subsequent anti-PD-1 treatment
One patient from the anti-PD-1 group in this study initially
received anti-CTLA-4, but developed severe immune-
related colitis and had to discontinue therapy. The patient
later developed additional metastasis and started anti-PD-1
(22 months after the end of anti-CTLA-4) therapy and had
a partial response within 3 months. Both pre-anti-CTLA-4
and pre-anti-PD-1 PBMC from this patient were evaluated
in this study. The two pre-treatment blood draws were
24 months apart and there was no recorded therapeutic
intervention between the two therapies. Comparison of the
viSNE map of the two samples revealed very low monocyte
counts in the pre-anti-CTLA-4 PBMC, but not in the pre-
anti-PD-1 sample (Additional file 1: Figure S11), which was
confirmed by manual gating (data not shown). Also, we ob-
served a significant reduction of CD14−CD33+ myeloid
cells in the pre-anti-PD-1 sample versus pre-anti-CTLA-4
PBMC. This highlights the power of viSNE in identifying
novel unanticipated cell populations. Whether these mye-
loid cells are functionally suppressive or not can only be
determined after further characterization. Other changes
observed in the pre-anti-PD-1 PBMC include an increase
in CD56hi NK cells, and increased CD27+ and CCR7+ CD4
+ cells. We hypothesize that this altered immune signature,
potentially a result of the anti-CTLA-4 treatment, played a
role in the positive clinical outcome after the PD-1 therapy.
Our data suggest that, while the anti-CTLA-4 treatment
did not halt disease progression, it may have reshaped the
immune system, and thereby allowed the patient to have a
partial response (PR) to the subsequent anti-PD-1 treat-
ment. However, we did not see general group-level differ-
ences between treatment naïve patients and those who had
previously received anti-CTLA-4 (data not shown), indicat-
ing that there may be case-by-case variations in the process
of immune re-shaping by prior immunotherapy.
Discussion
In this study, we report one of the first CyTOF analyses
on clinical samples from melanoma patients treated with
checkpoint blockade. Using two cohorts of patients
treated with anti-CTLA-4 or anti-PD-1 monotherapy,
we discovered completely different biomarker candidates
for the two immunotherapies. For anti-CTLA-4, we
found differences in CD4+ and CD8+ memory T cells
subsets between responders and non-responders. On the
other hand, responders and non-responders to anti-PD-
1 differed in CD69+ and MIP1β+ NK cell populations.
Due to the high dimensionality afforded by CyTOF, this
technology can enable us to detect novel (and often un-
expected) cell populations that play a role in anti-tumor
immunity. This, in turn will help in expediting clinical
biomarker discovery, which is critical to the implementa-
tion of cancer immunotherapy.
One of the major challenges in dealing with CyTOF
data, is performing high-dimensional data analysis [27].
viSNE offers visual presentation of the overall immune
landscape but does not provide statistical analyses. Citrus
is an automated algorithm designed to predict the differ-
ence between two datasets without bias from investigators.
However, this algorithm has limitations, including those
associated with the way that clusters are defined. In our
analysis, viSNE was used for visualization, and Citrus was
used for verification purposes only. Supervised manual
gating and multivariate analysis, which were done by sci-
entists with relevant expertise, were still the most trusted
approach to identify parameters that correlate with clinical
response. In this study, we discovered that a higher fre-
quency of memory T cells in baseline PBMC is a potential
biomarker candidate to predict clinical response to anti-
CTLA-4 treatment in advanced melanoma patients. On
the other hand, in anti-PD-1 treated patients, higher fre-
quency of NK cells (CD69+ and MIP-1β +) upon PMA+
Ionomycin stimulation ex vivo, potentially correlates with
positive response to therapy.
A recent study in our lab has shown that CD8+ Tcm
cells were important in predicting response to anti-
CTLA-4 and radiation combination therapy [28]. An-
other research study published recently also drew a cor-
relation between CD45RO+CD8+ memory T cells and
clinical response to anti-CTLA-4 therapy, but not anti-
PD-1 therapy in melanoma patients [29]. In this study,
we report that responders to anti-CTLA-4 monotherapy
have high baseline frequencies of CD4+ and CD8+ T cell
memory subsets, indicating that these memory subsets
play an important role in anti-CTLA4 blockade, and
warrant further investigation. Previous research in our
lab has shown that the addition of bevacizumab, an
angiogenesis blockade agent targeting Vascular Endothe-
lial Growth Factor (VEGF), to anti-CTLA-4 therapy in-
creased memory subsets in both the CD4+ and CD8+ T
cell compartments [30]. The findings described in this
study may provide an additional explanation for the ob-
served synergy between checkpoint blockade and angio-
genesis blockade. It will be interesting to determine if
higher baseline memory T-cell subsets can be a consistent
predictive biomarker for anti-CTLA-4 immunotherapy. In
addition, recent reports suggested that anti-PD-1 antibody
from different sources may have varying effects [31]. In
light of the complexity of the mechanism of action of
checkpoint blockade agents, the initial observations de-
scribed here will require further confirmation in prospect-
ive cohorts.
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Though T cells are believed to play the primary role in
the anti-tumor immunity of checkpoint blockade therap-
ies, the potential role of non-T cell populations cannot
be excluded. We found that a higher frequency of CD69
+ and MIP-1β+ NK cells upon in vitro stimulation is as-
sociated with better clinical response to anti-PD-1.
CD69 is an activation marker for lymphocytes including
NK cells. MIP-1β is a chemokine produced by macro-
phages, T and B cells, neutrophils, dendritic cells and
NK cells. It recruits pro-inflammatory cells, and induces
the production of pro-inflammatory cytokines [32]. It
is also important for the transendothelial migration of
NK cells, and also promotes Th1 skewing, which can
aid anti-tumor immunity. It is reasonable to assume
that the CD69+ and MIP-1β+ NK cells represent more
functionally active NK populations. However, our
multivariate analysis did not yield a strong predictive
model for response to anti-PD-1 therapy using either
PMA + Ionomycin stimulated data or unstimulated
data.
In a recent anti-PD-1 biomarker study, high relative
lymphocyte counts (≥17.5%) and high relative eosinophil
counts (≥1.5%) were found to be predictors of better sur-
vival [19]. Another study by Martens et al. showed that
low absolute monocyte count and high relative lympho-
cyte count were significantly associated with better sur-
vival in anti-CTLA-4 treated melanoma patients [18]. Our
study did not reveal predictive value for lymphocyte and
monocyte frequencies in the anti-CTLA-4 or anti-PD-1
cohorts (Additional file 1: Figure S2B and C). However, it
should be noted that relative subset frequency or percent-
age was examined in this study, and is a different meas-
urement from absolute cell count, which was the focus of
the other studies. Also, our sample processing protocol in-
cluded an overnight rest after thawing of samples. This
could have potentially led to losses and variability in
monocyte populations, making it hard to detect clear
differences between responders and non-responders.
Martens et al. also reported a correlation between
Treg frequencies with overall survival of patients.
However, our data did not show significant differ-
ences in Tregs between responders and non-
responders (Additional file 1: Figure S7). One possible
reason for this is that we defined Tregs as CD25
+CD127lo CD4+ T cells (our staining panel did not in-
clude FoxP3 which, being a transcription factor, re-
quires harsher permeabilization conditions). Furthermore,
we used a dichotomous stratification of patient outcome,
whereas the other group performed a correlative analysis
of these parameters with overall survival of patients. Fi-
nally, our assay platform is also different from these
previous studies. Further investigation is needed to
truly reveal all possible correlative parameters that
could predict response to immunotherapy.
Conclusions
Our findings suggest that response to anti-CTLA-4 and
anti-PD-1 in advanced melanoma patients is complex and
multifaceted. An improved understanding of factors that
influence the ability to mount an effective anti-tumor re-
sponse can inform our therapeutic strategies for melan-
oma and other diseases. Some of the findings in this study
are partly validated by another study published recently
which showed that memory subsets were predictive of re-
sponse to CTLA-4 blockade in melanoma patients [28].
Further studies using larger patient cohorts and different
types of cancer will also be invaluable in validating these
candidate biomarkers, and are already underway in our la-
boratory. These long-term rigorous biomarker discovery
efforts will not only help in patient selection, but will also
provide deeper insight into the mechanism of action of
these and other checkpoint blockade immunotherapies.
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